drugset / Trial / NCT06759636
A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11
RandomizedParallel-groupOpen-labelTreatment
Summary
FRIENDS-01：A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11
Timeline
- Start
- 2025-02-24
- Primary completion
- 2026-04-21
- Completion
- 2026-07-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Interleukin-11 | Protein / enzyme biologic | 25 ug/kg | Subcutaneous |
| Comparator | Interleukin-11 | Protein / enzyme biologic | 50 ug/kg | Subcutaneous |
| Subject | Romiplostim | Peptide | 3 ug/kg | Subcutaneous |